Results 21 to 30 of about 217,476 (395)
The Impact of Biomarkers in Pancreatic Ductal Adenocarcinoma on Diagnosis, Surveillance and Therapy
Cancers, 2022 Simple Summary Pancreatic ductal adenocarcinoma is a leading cause of cancer death worldwide. Due to the frequently late diagnosis, early metastasis and high therapy resistance curation is rare and prognosis remains poor overall.
N. Sturm, T. Ettrich, L. Perkhofer
semanticscholar +1 more source
Familial Pancreatic Ductal Adenocarcinoma [PDF]
The American Journal of Pathology, 2019 Pancreatic ductal adenocarcinoma (PDAC), although a rare disease, has a poor prognosis. With 5-year overall survival of 8%, there is a critical need to detect PDAC early or at a premalignant stage. Current screening methods are largely imaging based, but a more focused screening approach based on modifiable and nonmodifiable risk factors may improve ...
Kelly E, Diaz, Aimee L, Lucas
openaire +2 more sources
Molecular Therapy: Nucleic Acids, 2022 This research developed an easy-to-use, reproducible pancreatic cancer animal model utilizing pancreas-targeted hydrodynamic gene delivery to deliver human pancreatic cancer-related genes to the pancreas of wild-type rats.
Osamu Shibata +12 more
doaj +1 more source
Frontiers in Oncology, 2021 Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis, with a median survival time of 10-12 months. Clinically, these poor outcomes are attributed to several factors, including late stage at the time of diagnosis impeding resectability, as well ...
D. Principe +5 more
semanticscholar +1 more source
The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment
Technology in Cancer Research & Treatment, 2020 Pancreatic ductal adenocarcinoma has extremely high malignancy and patients with pancreatic ductal adenocarcinoma have dismal prognosis. The failure of pancreatic ductal adenocarcinoma treatment is largely due to the tumor microenvironment, which is ...
Hongzhi Sun MMed +2 more
doaj +1 more source
Journal of Translational Medicine, 2019 Background A hallmark of pancreatic ductal adenocarcinoma is the desmoplastic reaction, but its impact on the tumor behavior remains controversial.
Fabio Grizzi +18 more
doaj +1 more source
Cancer Discovery, 2019 Cancer-associated fibroblasts (CAFs) are major players in the progression and drug resistance of pancreatic ductal adenocarcinoma (PDAC). CAFs constitute a diverse cell population consisting of several recently described subtypes, although the extent of ...
Ela Elyada +21 more
semanticscholar +1 more source
Cellular and molecular mechanisms of perineural invasion of pancreatic ductal adenocarcinoma
Cancer Communications, 2021 Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignant disease with a unique tumor microenvironment surrounded by an interlaced network of cancer and noncancerous cells.
Jingbo Li, R. Kang, D. Tang
semanticscholar +1 more source
Desmoplasia of Pancreatic Ductal Adenocarcinoma [PDF]
Clinical Gastroenterology and Hepatology, 2009 Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and is characterized by remarkable desmoplasia. The desmoplasia is composed of extracellular matrix (ECM) proteins, myofibroblastic pancreatic stellate cells, and immune cells associated with a multitude of cytokines, growth factors, and ECM metabolizing enzymes.
Stephen, Pandol +4 more
openaire +2 more sources